Amryt Pharma PLC Directorate Change (3896W)
February 09 2017 - 1:00AM
UK Regulatory
TIDMAMYT
RNS Number : 3896W
Amryt Pharma PLC
09 February 2017
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Directorate Change
Amryt, the pharmaceutical company focused on best-in-class
treatments for rare and orphan diseases, announces that
Non-executive Director, Cathal Friel, will be stepping down from
the Board of Directors on 31 March 2017.
The Board would like to thank Cathal for his significant
contribution to the Company, in particular with the admission of
Amryt's shares to AIM and ESM in April 2016 via the reverse
takeover of Fastnet Equity plc, where Cathal was Executive
Chairman. Cathal will have served on Amryt's Board for
approximately a year since that date and now steps down to focus on
his other business interests.
Harry Stratford, Chairman of Amryt, commented:
"Cathal has seen the business achieve very significant
milestones in its first year. I would like to thank him for his
extremely important contribution during the reverse takeover and
for his guidance during our first year as a public company. We wish
him well for the future."
Cathal Friel, commented:
"Having helped Amryt with its admission to AIM and over its
first full year as a public company, I leave the Board with great
confidence in the executive team and remain very excited about the
Group's future potential."
Enquiries:
Amryt Pharma plc C/o KTZ Communications
Joe Wiley, CEO
Rory Nealon, CFO/COO
+44 (0) 20
Shore Capital 7408 4090
Nomad and Joint Broker
Bidhi Bhoma, Edward Mansfield
+353 (1) 679
Davy 6363
ESM Adviser and Joint
Broker
John Frain, Anthony Farrell
+44 (0) 20
Stifel 7710 7600
Joint Broker
Jonathan Senior, Ben
Maddison
+44 (0) 20
KTZ Communications 3178 6378
Katie Tzouliadis, Emma
Pearson
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
It recently acquired an exclusive licence to sell LOJUXTA
(lomitapide), across the EU and other territories including the
Middle East, North Africa, Turkey and Israel. LOJUXTA is used to
treat a rare life-threatening disease called Homozygous Familial
Hypercholesterolemia.
Amryt's lead development product, AP101 (Episalvan), received
marketing approval for the treatment of partial-thickness wounds
from the European Commission in January 2016. Amryt intends to
develop AP101 (Episalvan) as a new treatment for Epidermolysis
Bullosa ("EB"), a rare and distressing genetic skin disorder
affecting young children for which there is currently no treatment.
The Company is currently planning a Phase 3 study of AP101
(Episalvan) in EB, which has been granted US and EU orphan drug
designation. The market opportunity for EB is estimated to be circa
EUR 1.3 billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease. AP102 was recently granted orphan designation in
the US in acromegaly by the FDA.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFSDFTITIID
(END) Dow Jones Newswires
February 09, 2017 02:00 ET (07:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024